Marshall Wace, LLP Pliant Therapeutics, Inc. Transaction History

Marshall Wace, LLP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$14.14 - $19.59 $1.85 Million - $2.57 Million	130,935 New	130,935 $1.95 Million
Q3 2023 Nov 14, 2023	BUY	$14.58 - $20.15 $1.08 Million - $1.49 Million	73,921 New	73,921 $1.28 Million
Q1 2023 May 15, 2023	SELL	$18.73 - $36.26 $533,168 - $1.03 Million	-28,466 Reduced 43.25%	37,354 $993,000
Q4 2022 Feb 14, 2023	BUY	$17.0 - $25.43 $1.12 Million - $1.67 Million	65,820 New	65,820 $1.27 Million
Q2 2022 Aug 15, 2022	BUY	$4.11 - $8.75 $190,761 - $406,122	46,414 New	46,414 $371,000

168

63.2M

245K

373K

Ticker PLRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,682,000
Market Cap $600M
Description
Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a tri...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.